GlassScriptPhysician profile
Christine Kannler
NPI 1083681795
$3,900.75
in general payments reported to CMS, 2019-2025
25 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $73.88 · 2021: $225 · 2022: $684 · 2023: $1,014 · 2024: $650 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,691.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $717.74 | 2022-2025 | |
| Janssen Biotech, INC. | $522.64 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $297.12 | 2021-2025 | |
| Celgene Corporation | $296.30 | 2019-2024 | Sotyktu |
| Leo Pharma INC. | $285.70 | 2022-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $229.54 | 2022-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $203.78 | 2023-2025 | Sotyktu |
| Incyte Corporation | $162.95 | 2022-2025 | Opzelura |
| Ucb, INC. | $159.99 | 2020-2025 | Bimzelx |
| Organogenesis INC. | $158.55 | 2020-2025 | Puraply, Novachor, Via Matrix |
| Regeneron Healthcare Solutions, INC. | $148.28 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $135.39 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $101.15 | 2024-2025 | |
| Amgen INC. | $100.04 | 2021-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $91.54 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $76.03 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $51.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.49 | 2023 | Spevigo |
| Galderma Laboratories, L.P. | $28.55 | 2020-2025 | Nemluvio |
| Botanix Sb INC | $22.51 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $21.89 | 2025 | |
| Dermavant Sciences, INC. | $18.25 | 2023 | Vtama |
| Mylan Pharmaceuticals INC. | $15.89 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.02 | 2024 | Ycanth |
| Organon LLC | $8.67 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Kannler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.